title: Ramipril: a review of the new ACE inhibitor.
abstract: Ramipril is a long acting angiotensin converting enzyme (ACE) inhibitor, which exhibits similar pharmacodynamic properties to Captopril and Enalapril. Like Enalapril, it is a prodrug, which is hydrolyzed after absorption to form the active metabolite ramiprilat which has a long elimination half-life, permitting once daily administration. In the dose range 2.5-10 mg once daily the drug has been effective and well tolerated during treatment for up to two years. In dosages of 5 or 10 mg once daily the antihypertensive efficacy of Ramipril was comparable with usual therapeutic dosages of Captopril, Enalapril, and Atenolol.
authors.affiliation: Arkansas Children's Hospital, Little Rock.
authors.forename: T P
authors.initials: TP
authors.lastname: Mills
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006977:Hypertension, Renal / Q000188:drug therapy; D011355:Prodrugs; D017257:Ramipril
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001643:Bridged Bicyclo Compounds; D011355:Prodrugs; D017257:Ramipril